NCT01558869已完成2 期
An Open-label, Single-centre, Single-arm Phase II Study of Capecitabine Combined With Oxaliplatin and Irinotecan (Xeloxiri) as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- Change in extent of disease
研究概览
简要总结
This is an open-label, single centre, single-arm phase II study which aims to assess the efficacy and tolerability of triplet combination of capecitabine, oxaliplatin and irinotecan (Xeloxiri regimen) in treating patients with advanced unresectable pancreatic carcinoma. Clinical data from patients diagnosed with pancreatic adenocarcinoma will be collected and analyzed in this study. The patients' data will be collected and maintained in the Division of Medical Oncology of the University Department of Medicine, Queen Mary Hospital, Hong Kong.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults ≥ 18 years of age, male or female.
- •Histopathologically or cytologically confirmed adenocarcinoma of the pancreas.
- •ECOG performance status 0 to
- •Adequate bone marrow reserve.
- •Absolute neutrophil count > 1x10^9/L.
- •Total bilirubin <3 times the upper limit of the normal range.
- •Life expectancy ≥ 12 weeks.
- •Signed written informed consent form.
排除标准
- •Prior malignant disease other than pancreatic cancer.
- •Patients suitable for surgical or locoregional therapies.
- •Patients who have prior anticancer therapy for pancreatic cancer.
- •Patients unable to swallow oral medications.
- •Any evidence of brain metastasis (unless the patient is >6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry).
- •Active clinically serious infections (> grade 2 NCI / CTC Adverse Event version 3.0).
- •History of allergy to platinum compounds.
- •Patients who have chronic inflammatory bowel disease and/or bowel obstruction.
- •Patients who have severe bone marrow failure.
- •Patients undergoing renal dialysis.
- •History of HIV infection.
- •Seizure disorder requiring medication (such as steroids or anti-epileptics).
- •Women who are pregnant or breast-feeding, or women of child-bearing potential who are unable or unwilling to practice a highly effective means of contraception.
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of study results.
研究组 & 干预措施
Arm 1
Experimental
干预措施: Capecitabine (Drug)
Arm 1
Experimental
干预措施: Oxaliplatin (Drug)
Arm 1
Experimental
干预措施: Irinotecan (Drug)
结局指标
主要结局
Change in extent of disease
时间窗: Change from baseline in size approximately every 4 cycles
Objective response rate
次要结局
- CA19.9 reduction(Change from baseline every 2 cycles)
- Progression-free survival(From date of start until the date of first documented progression or death from disease-related causes or last follow-up, whichever came first, assessed up to 18 months)
- Overall survival(From date of start until the date of death from any cause or last follow-up, whichever came first, assessed up to 18 months)
研究者
Dr. YAU Chung Cheung Thomas
Clinical Assistant Professor
The University of Hong Kong
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal CancerColorectal CancerNCT03146377The University of Hong Kong32
Unknown
2 期
A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous ChemotherapyUnresectable Metastatic Colorectal CancerNCT04866108Beijing Friendship Hospital49
已完成
2 期
Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic CancerPancreatic NeoplasmsNCT05481463Sun Yat-sen University22
进行中（未招募）
2 期
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic CancerPancreatic NeoplasmsNCT05481476Sun Yat-sen University32
Unknown
2 期
A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCLRR DLBCL; PD-1; CD20NCT05178836Shandong New Time Pharmaceutical Co., LTD62